Please try another search
For the three months ended 31 March 2020, Portola Pharmaceuticals Inc revenues increased 19% to $26.4M. Net loss decreased 12% to $68.8M. Revenues reflect Product revenue, net increase of 26% to $25.6M. Lower net loss reflects Stock-based Compensation in R&D decrease of 74% to $2.6M (expense), Research and development - Balancing val decrease of 8% to $23.5M (expense), Excess and obsolescence charge decrease of 46% to $2.1M (expense).
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 26.39 | 29.25 | 36.8 | 28.42 |
Gross Profit | 24.17 | 13.39 | 34.41 | 23.33 |
Operating Income | -58.44 | -90.14 | -43.58 | -63.96 |
Net Income | -68.77 | -96.68 | -49.63 | -66.2 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 513.31 | 578.48 | 577.18 | 366.5 |
Total Liabilities | 441.27 | 448.66 | 364.3 | 365.9 |
Total Equity | 72.03 | 129.82 | 212.89 | 0.59 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 9 Months | 6 Months |
Cash From Operating Activities | -71.1 | -237.92 | -164.59 | -117.7 |
Cash From Investing Activities | 52.93 | -73 | 5.61 | 89.59 |
Cash From Financing Activities | 0.1 | 389.56 | 326.35 | 75.81 |
Net Change in Cash | -18.09 | 78.64 | 167.45 | 47.65 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review